Orchestra BioMed Holdings Past Earnings Performance
Past criteria checks 0/6
Orchestra BioMed Holdings's earnings have been declining at an average annual rate of -31.9%, while the Medical Equipment industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 16.8% per year.
Key information
-31.9%
Earnings growth rate
56.5%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 16.8% |
| Return on equity | -72.2% |
| Net Margin | -1,779.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Orchestra BioMed Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -49 | 20 | 34 |
| 30 Sep 23 | 4 | -48 | 19 | 33 |
| 30 Jun 23 | 4 | -45 | 18 | 30 |
| 31 Mar 23 | 4 | -41 | 16 | 27 |
| 31 Dec 22 | 4 | -34 | 14 | 22 |
| 30 Sep 22 | 0 | -32 | 13 | 18 |
| 30 Jun 22 | 0 | -27 | 9 | 16 |
| 31 Mar 22 | -1 | -25 | 8 | 13 |
| 31 Dec 21 | -1 | -23 | 8 | 13 |
| 31 Dec 20 | 6 | -21 | 11 | 13 |
Quality Earnings: OBIO is currently unprofitable.
Growing Profit Margin: OBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if OBIO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare OBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OBIO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.6%).
Return on Equity
High ROE: OBIO has a negative Return on Equity (-72.19%), as it is currently unprofitable.